Works Cited

1. Byham-Gray LD. Diabetic kidney disease. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

2. Burrows NR, Hora I, Geiss LS, Gregg EW, Albright A. Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes—United States and Puerto Rico, 2000–2014. MMWR. 2017;66(43):1165-1170.

3. United States Renal Data System Annual Data Report 2018: Epidemiology of Kidney Disease in the United States. Available at https://www.usrds.org/adr.aspx. Last accessed November 12, 2018.

4. Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 4th ed. Chicago, IL: American Association of Diabetes Educators; 2017.

5. Westerfield J, Holcomb S, Jensen S (eds). Current Trends in Diabetes Management: A Guide for the Healthcare Professional. 7th ed. Nashville, TN: Healthways; 2008.

6. Bardsley JK, Magee MF. Pathophysiology of the metabolic disorder. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

7. American Diabetes Association. Fast Facts: Data and Statistics About Diabetes. Available at https://professional.diabetes.org/content/fast-facts-data-and-statistics-about-diabetes. Last accessed November 12, 2018.

8. Centers for Disease Control and Prevention. United States Diabetes Surveillance System. Diagnosed Diabetes. Available at https://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html. Last accessed November 12, 2018.

9. Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practice. 2nd ed. New York, NY: Informa Healthcare; 2008.

10. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Available at https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Last accessed November 12, 2018.

11. Colberg S, Friesz M. Diabetes Free Kids: A Take Charge Plan for Preventing and Treating Type 2 Diabetes in Children. New York, NY: Avery; 2005.

12. American Diabetes Association. Gestational Diabetes. Available at http://www.diabetes.org/diabetes-basics/gestational. Last accessed November 12, 2018.

13. Childs BP, Cypress M, Spollett G (eds). Complete Nurse's Guide to Diabetes Care. 2nd ed. Alexandria, VA: American Diabetes Association; 2009.

14. Tucker ME. USPSTF: Screen Everyone 45 and Older for Abnormal Glucose. Available at https://www.medscape.com/viewarticle/832850. Last accessed November 12, 2018.

15. U.S. Preventive Services Task Force. Final Recommendation Statement: Abnormal Blood Glucose and Type 2 Diabetes Mellitus: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/screening-for-abnormal-blood-glucose-and-type-2-diabetes. Last accessed November 12, 2018.

16. American Diabetes Association. Standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S1-S159.

17. American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.

18. Edelman SV, Henry RR. Diagnosis and Management of Type 2 Diabetes. 12th ed. New York, NY: Professional Communications, Inc.: 2013.

19. Venes D (ed). Taber's Cyclopedic Medical Dictionary. 23rd ed. Philadelphia, PA: FA Davis Company; 2017.

20. PerlmanRL, Heung M, Ix JH. Renal disease. In: McPhee SJ, Lingappa VR, Ganong WF (eds). Pathophysiology of Disease: An Introduction to Clinical Medicine. 7th ed. New York, NY: McGraw Hill; 2014.

21. Lyn S. Smart Charts: Physiology. New York, NY: Lange; 2004.

22. Urden L, Stacy K, Lough M. Critical Care Nursing: Diagnosis and Management. 8th ed. St. Louis, MO: Mosby; 2017.

23. Huether SE, McCance KL (eds). Understanding Pathophysiology. 6th ed. St. Louis, MO: Elsevier; 2016.

24. Mindell JA, Chertow GM. A practical approach to acute renal failure. Med Clin North Am. 1997;81(3):731-748.

25. Workeneh BT, Agraharkar M, Gupta R. Acute Kidney Injury. Available at https://emedicine.medscape.com/article/243492-overview. Last accessed November 12, 2018.

26. Levine DZ. Caring for the Renal Patient. 3rd ed. Philadelphia, PA: Saunders; 1997.

27. Baumgarten M, Gehr T. Chronic kidney disease: detection and evaluation. Am Fam Physician. 2011;84(10):1138-1148.

28. Barri Y, Golper TA. Unique Aspects of Gastrointestinal Disease in Dialysis Patients. Available at https://www.uptodate.com/contents/unique-aspects-of-gastrointestinal-disease-in-dialysis-patients. Last accessed November 12, 2018.

29. Bloomgarden ZT. Diabetic nephropathy. Diabetes Care. 2008;31(4):823-827.

30. Basi S, Fesler P, Mimran A, Lewis JB. Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander? Diabetes Care. 2008;31(Suppl 2):S194-S201.

31. Ossman SS. Diabetic nephropathy: where we have been and where we are going. Diabetes Spec. 2006;19(3):153-156.

32. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4): 556-563.

33. Maahs DM, Snively BM, Bell RA, et al. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care. 2007;30(10):2593-2598.

34. Taniwaki H, Nishizawa Y, Kawagishi T, et al. Decrease in glomerular filtration rate in Japanese patients with type 2 diabetes is linked to atherosclerosis. Diabetes Care. 1998;21(11):1848-1855.

35. Paige NM, Nagami GT. The top 10 things nephrologists wish every primary care physician knew. Mayo Clin Proc. 2009;84(2): 180-186.

36. Heintz B, Stöcker G, Mrowka C, et al. Decreased glomerular basement membrane heparan sulfate proteoglycan in essential hypertension. Hypertension. 1995;25(3):399-407.

37. Mogensen CE. Renal dysfunction and hypertension. In: Goldstein BJ, Müller-Wieland D (eds). Type 2 Diabetes: Principles and Practices. 2nd ed. New York, NY: Informa; 2008: 263-276.

38. Diabetes in Control. ADA Standards Highlight GFR Screening for Nephropathy. Available at http://www.diabetesincontrol.com/ada-standards-highlight-gfr-screening-for-nephropathy. Last accessed November 12, 2018.

39. Stults B, Jones RE. Management of hypertension in diabetes. Diabetes Spectrum. 2006;19(1):25-31.

40. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832-1839.

41. U.S. Food and Drug Administration. FDA Drug Safety Communication: New Warnings for Using Gadolinium-Based Contrast Agents in Patients with Kidney Dysfunction. Available at https://www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Last accessed November 12, 2018.

42. Brown J, Thompson C. Contrast-induced acute kidney injury: the at-risk patient and protective measures. Curr Cardiol Rep. 2010;12(5):440-445.

43. Basu A. Contrast-Induced Nephropathy. Available at https://emedicine.medscape.com/article/246751-overview. Last accessed November 12, 2018.

44. Herrada B, Agarwal J, Abcar AC. How can we reduce the incidence of contrast-induced acute renal failure? Perm J. 2005;9(3): 58-60.

45. National Kidney Foundation. Contrast Dye and the Kidneys. Available at https://www.kidney.org/atoz/content/Contrast-Dye- and-Kidneys. Last accessed November 12, 2018.

46. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.

47. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17(1):S29-S36.

48. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.

49. Cornell S, Sisson, E.M. Pharmacotherapy: dyslipidemia and hypertension in persons with diabetes. In: Mensing C (ed). The Art and Science of Diabetes Self-Management Education: A Desk Reference for Healthcare Professionals. 3rd ed. Chicago, IL: American Association of Diabetes Educators; 2014.

50. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-176.

51. Dinwiddie LC, Burrows-Hudson S, Peacock EJ. Stage 4 chronic kidney disease: preserving kidney function and preparing patients for stage 5 kidney disease. Am J Nurs. 2006;106(9):40-51.

52. Kidney Disease Outcomes Quality Initiative. Clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530.

53. Akizawa T, Gejyo F, Nish S, et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Ther Apher Dial. 2011;15(5):431-440.

54. U.S. Food and Drug Administration. FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease. Available at https://www.fda.gov/Drugs/DrugSafety/ucm259639.htm. Last accessed November 12, 2018.

55. Lexicomp Online. Available at http://online.lexi.com. Last accessed November 12, 2018.

56. RxList. Omontys. Available at https://www.rxlist.com/omontys-drug.htm#description. Last accessed November 12, 2018.

57. KDOQI Clinical Practice Guidelines for vascular access. Am J Kidney Dis. 2006;48(Suppl 1):S176-S247.

58. Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL. Brenner and Rector's The Kidney. 10th ed. Philadelphia, PA: Saunders; 2015.

59. Beathard G. A practitioner's resource guide to hemodialysis arteriovenous fistulas. ESRD Network Tex. 2003;(Suppl).

60. Lomonte C, Basile C. Preoperative assessment and planning of hemodialysis vascular access. Clin Kidney J. 2015;8(3):278-281.

61. Santoro D, Benedetto F, Mondello P, et al. Vascular access for hemodialysis: current perspectives. Int J Nephrol Renovasc Dis. 2014;7:284-294.

62. Drew DA, Lok CE. Strategies for planning the optimal dialysis access for an individual patient. Curr Opin Nephrol Hypertens. 2014;23(3):314-320.

63. Tordoir JH, Bode AS, van Loon MM. Preferred strategy for hemodialysis in access creation in elderly patients. Eur J Vasc Endovasc Surg. 2015;49(6):738-743.

64. Mansilla AV, Toombs BD, Vaughn WK, Zeledon JI. Patency and life-spans of failing hemodialysis grafts in patients undergoing repeated percutaneous de-clotting. Tex Heart Inst J. 2001;28(4):249-253.

65. Zaleski G. Declotting, maintenance, and avoiding procedural complications of native arteriovenous fistulae. Semin Intervent Radiol. 2004;21(2):83-93.

66. Centers for Medicare and Medicaid Services. Center for Clinical Standards and Quality. CMS ESRD Measured Manual for the 2018 Performance Period/2020 Payment Year v3.0. Available at https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/ESRDQIP/Downloads/ESRD-Manual-v30.pdf. Last accessed November 12, 2018.

67. Bloomgarden ZT. Inpatient diabetes control: rationale. Diabetes Care. 2004;27(8):2074-2080.

68. Guest S, Akonur A, Ghaffari A, Sloand J, Leypoldt JK. Intermittent peritoneal dialysis: urea kinetic modeling and implications of residual kidney function. Perit Dial Int. 2012;32(2):142-148.

69. Asghar RB, Bandyopadhay S, Woywodt A. Intermittent peritoneal dialysis: just enough for some or inadequate altogether? Perit Dial Int. 2012;32(2):134-136.

70. Organ Procurement and Transplantation Network. Policies: Allocation of Kidneys. Available at https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf. Last accessed November 12, 2018.

71. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011;86(5):444-456.

72. U.S. Department of Health and Human Services. Office of Disease Prevention and Health Promotion. America's Health Literacy: Why We Need Accessible Health Information. Available at https://health.gov/communication/literacy/issuebrief. Last accessed November 12, 2018.

Evidence-Based Practice Recommendations Citations

1. Management of Chronic Kidney Disease Working Group. VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care. Washington, DC: Department of Veterans Affairs, Department of Defense; 2014. Available at https://www.healthquality.va.gov/guidelines/CD/ckd/VADoDCKDCPG2014.pdf. Last accessed November 12, 2018.

2. American Dietetic Association. Chronic Kidney Disease Evidence-Based Nutrition Practice Guideline. Chicago, IL: American Dietetic Association; 2010. Available at https://www.andeal.org/topic.cfm?cat=3927. Last accessed November 12, 2018.


Copyright © 2018 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.